SIGA stock information

Sector:

Healthcare

Description:

SIGA Technologies, Inc., a commercial-stage pharmaceutical company, focuses on the health security and infectious disease markets in the United States. Its lead product is TPOXX, an oral formulation antiviral drug for the treatment of human smallpox disease caused by variola virus. SIGA Technologies, Inc. has a strategic partnership with Cipla Therapeutics to deliver sustained innovation and access to antibacterial drugs primarily against biothreats. The company was incorporated in 1995 and is headquartered in New York, New York.

SIGA Technologies, Inc. website

Current Price

$5.60

RSI

49.11

Market Capitalization:

535.1M

Beta:

0.493

Volume:

446,602

Analyst Target Price:

$ 11

Economiic Fair Price:

Earnings DateNovember 03, 2022

Report DateNovember 03, 2022

QuarterQ3

Forward Dividend N/A

Forward Dividend Rate N/A

Dividend N/A

Dividend Rate N/A

Payout Ratio N/A

Cash

Debt

EPS0.907

Profit Margin52.00 %

Revenue Per Share TTM1.775

Return On Equity TTM0.457

YoY Revenue Growth (TTM)

451.84 %

YoY Pre Tax Income Growth (TTM)

505.28 %

YoY Free Cash Flow (TTM)

191.17 %

QoQ Revenue Growth

1390.07 %

QoQ Pre Tax Income Growth

1182.59 %

QoQ Free Cash Flow Growth

-393.58 %

2021 Revenue

$ 133.7M

6.97 %

2020 Revenue

$ 125M

367.28 %

2019 Revenue

$ 26.7M

-94.39 %

2018 Revenue

$ 477.1M

3788.30 %

2017 Revenue

$ 12.3M

-18.14 %

2016 Revenue

$ 15M

2021 Free Cash Flow

$ 11.4M

-84.00 %

2020 Free Cash Flow

$ 71.5M

492.16 %

2019 Free Cash Flow

$ -18.2M

-126.51 %

2018 Free Cash Flow

$ 68.8M

932.71 %

2017 Free Cash Flow

$ -8.3M

92.86 %

2016 Free Cash Flow

$ -115.6M

2021 Pre Tax Income

$ 89.3M

21.50 %

2020 Pre Tax Income

$ 73.5M

822.20 %

2019 Pre Tax Income

$ -10.2M

-102.47 %

2018 Pre Tax Income

$ 411.6M

1173.96 %

2017 Pre Tax Income

$ -38.3M

3.41 %

2016 Pre Tax Income

$ -39.7M

SIGA Technologies, Inc.(SIGA)